autologous anti-HER2 TAC T cells TAC01-HER2

{
  "id": "MLC-T-ONC-011453",
  "term": "autologous anti-HER2 TAC T cells TAC01-HER2",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes that are genetically engineered with a T-cell Antigen Coupler (TAC), comprising of a domain that targets the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2) and another domain that binds to the endogenous T-cell receptor (TCR), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-HER2 TAC T cells TAC01-HER2 targets and binds to HER2-expressing tumor cells and activates TCR-mediated signaling pathways, leading to T-cell-mediated killing of HER2-expressing tumor cells. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by a variety of cancers.",
  "synonyms": [
    "autologous anti-HER2 T-cell antigen coupler-expressing T cells TAC01-HER2",
    "TAC-engineered T cells TAC01-HER2"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-anti-her2-tac-t-cells-tac01-her2/"
}